Corporate Finance

Patagonia Gold celebrates first gold from its Calcatreu mine, a major operational win that ignites Argentina's Rio Negro economy amid deep-seated local dissent.

As the Pentagon scrambles for battle-tested autonomous weapons, a new partnership promises to deliver. But is fast-tracking foreign tech the answer or a risky bet?

VENU's $50M sale-leaseback fuels a rapid expansion. But is its innovative financial model a new blueprint for growth or a high-stakes bet on the future?

Ares Capital, a giant in middle-market finance, just opened a new $1B funding spigot. Is this a blueprint for the BDC industry or a sign of cheaper capital for American businesses?

With a new CMO known for getting drugs approved, Protego Biopharma is betting big on its novel approach to treating a devastating rare disease.

A silent demographic cliff threatens trillions in assets. With 75% of advisors unprepared for transition, a new framework argues for legacy over exit.

Rokid's $4M Makuake success isn't just a record; it's a signal. With AI translation as the killer app, are smart glasses finally moving from niche to necessary?

The Stoneport Commodity ETF is liquidating after just seven months. Its story reveals the harsh, unsentimental system governing the competitive ETF market.

A small biotech is about to reveal data on a novel drug that could change autoimmune care. Will its bold scientific strategy pay off for patients and investors?

As Pacira BioSciences fends off an activist investor, a high-stakes proxy fight pits long-term R&D against demands for short-term returns.

As AI and crypto converge, a new project bets its future not on speculation, but on tangible utility and verifiable security. We deconstruct the model.

A small biotech just unveiled data for an oral weight-loss pill that appears twice as effective as a key competitor in early tests, shaking up the market.

After its ratings were affirmed, Jordan's MEICO chose to exit AM Best's process. Is this a savvy move to cut costs or a gamble with market transparency?

The S&P/TSX Composite's latest rebalance is more than a market footnote. It's a story of rising commodity players and struggling consumer-facing firms.

Beyond the pitch, a massive government investment aims to leverage the FIFA World Cup to overhaul Canada's sport system and unite a nation.

Allen Control Systems' massive funding for its autonomous Bullfrog weapon reveals a new reality: venture capital is now funding the future of warfare.

A new contract for 243 school workers is more than a local labor win. It’s a strategic investment in the human infrastructure that makes learning possible.

AM Best's stable outlook for Korea P&I isn't just a rating change. It's a validation of a tough, calculated strategy to reduce risk and leverage state support.

SurgePays is building a powerful AI to serve 138 million subprime consumers. But as we chase innovation, we must ask: is this the path to equity or a new digital trap?

Set to join the Russell 3000, Starfighters Space and its unique F-104 fleet bring Wall Street's focus to a new class of aerospace infrastructure.